BHR Biosynex has welcomed over sixty guests representing NHS Trusts, private healthcare companies, and the in vitro diagnostics industry, for the official opening of its new state-of-the-art premises in Nuneaton.
The well-attended event reflected on the company’s achievements to drive point of care diagnostics in the UK over the past 34 years, showcasing the breadth of products in their product portfolio and hinted at what is yet to come.
.jpg)
First established in 1990, BHR Pharmaceuticals acquired the rights to sell the Cameo pregnancy test in the UK in 1993, then continued to expand its point of care testing portfolio across a variety of diagnostic areas. In 1999, the company introduced the first handheld cholesterol test to the UK market: the BioScanner 2000.
In 2009, the NHS Health Check was introduced in the UK and the company’s CardioChek solution was the only handheld device among three solutions approved for use as part of the programme. Today, the company is a market leader in point of care cholesterol testing. Over 12,000 cholesterol analysers are currently being used in the UK and over 9,000,000 cholesterol tests have been carried out using the CardioChek System.
.jpg)
During the event, the company also discussed the importance of point of care diagnostics and the benefits to UK healthcare systems with the Rt Hon Marcus Jones MP. With the roll out of community diagnostic centres and virtual wards, there is an increased focus on delivering convenient and rapid test results at the point of care and within community settings – to improve efficiency of patient pathways, reduce healthcare inequalities, and improve outcomes through earlier diagnosis. BHR Biosynex is well positioned to support the NHS in achieving these ambitions, providing a range of innovative point of care solutions that meet the needs of an evolving integrated healthcare system.
The company has also been supporting UK healthcare on a variety of key projects, including Warwick University – working with Professor Saravanan on a study of HbA1c testing in early pregnancy to predict gestational diabetes; and UCL & Eastman Dental on the impact of diabetes on dental implants.
In 2022, BHR Pharmaceuticals was acquired by Biosynex – a major player in the design, manufacture, and distribution of rapid diagnostic tests, with a presence in more than 90 countries worldwide. The acquisition by Biosynex has strengthened the organisation’s proposition to reinforce market presence in the UK. Under the BHR Biosynex brand name, the company is now looking to the future with its new 7,043 square foot building, a strong customer-focused team, and an expanding portfolio of solutions to meet the needs of an evolving healthcare system.
Ramesh Patel, managing director of BHR Biosynex, said: “The opening event has given us the perfect opportunity to showcase our premises and our people, but most importantly the ethos of the company. We aim to provide our customers with the innovative point of care solutions they need to deliver quality healthcare services to their patients. I am immensely proud of the team and genuinely excited for the future of BHR Biosynex.”
.jpg)
